1 0 0 6) and suggesting that there was substantial correlation between SNPs. This correlation is 1 0 1 expected, due to the close proximity of SNPs in WGS data which leads to linkage 1 0 2 disequilibrium and the non-independence of tests. As such, genome-wide significance was 1 0 3 determined using the permutation adjusted p-permutation adjusted p-value threshold. SNPs Validating GWAS with known DR variants 1 0 8 GWAS was performed to identify variants associated with drug resistance. The drug 1 0 9 resistance phenotype was binary for each drug and defined as any history, or not, of failure 1 1 0 while treated with the given drug. Failure was defined as at least one measure of viral load 1 1 1 >1000 copies/ml after 12 months of treatment. GWAS identified eight independent 1 1 2 associations at permutation adjusted genome-wide significance. Five of the associations were 1 1 3 known loci involved in DR and all but one were in the reverse transcriptase region (RT), the 1 1 4 functional target of these drugs (see Table 2 ). Failure on tenofovir was associated with three 1 1 5 known SNPs (2730G, 2852A and 2880T, see Figure 1 ) in the RT region, at amino acid 1 1 6 positions 65, 106, and 115, of which position 65 and 115 were known tenofovir DR variants 1 1 7 and position 106 was previously associated with DR with the most common drugs used in While our analyses identified several known variants for DR, not all were identified. However, it is well known in GWAS studies that sample size is a critical limitation, with 1 2 7 additional SNPs identified when larger samples are available. We observed a weak positive 1 2 8 correlation in our analyses between the number of significant associations per drug and 1 2 9 sample size (R 2 =22%). Looking at known DR mutations [18] with data available showed an 1 3 0 excess of significant associations compared to expectation by chance, with 12% containing a 1 3 1 variant at genome-wide significance and a further 41% containing at least one at nominal 1 3 2 significance, despite incomplete coverage (p<0.001; see Supplementary Table 2 ). This trend 1 3 3 was especially clear within the primary resistance mutations. 1 3 4 1 3 5 As well as known drug resistance variants, additional associations were observed. The 1 3 6 first was two associations within RT amino acid 68. The first was between tenofovir failure 1 3 7 and SNP 2738G resulting in a change from serine to glycine. Replication was performed 1 3 8 using the Stanford University HIV Drug Resistance Database [19, 20] . Subtype C sequences however, 5.5% had glycine at this position (n=488, p<0.0001 compared to non exposed 1 4 2 distribution). Stavudine resistance was showed associations with a different SNP (2739A) 1 4 3 from serine to asparagine ( Supplementary Figure 3 ). However further investigation showed 1 4 4 this to be an association with the negatively correlated drug tenofovir which had a p-value 1 4 5 just below genome-wide significance for this SNP (p=7.1E-4). This was clear both from the 1 4 6 fact the reference sequence allele was associated with stavudine DR, and from the results of 1 4 7 the replication. For sequences failing on tenofovir 4.7% had asparagine at position 68 1 4 8 (p<0.0001), while for sequences failing on stavudine (n=2,800) no asparagine variants were 1 4 9 observed. While not known drug resistance variants, amino acid 68 (specifically the change 1 5 0 to glycine) has been suggested as a compensatory mutation for reduced fitness due to the 1 5 1 drug resistance variant in amino acid 65 [21, 22] . Indeed epistasis was observed between the 1 5 2 significant SNPs in amino acid 68 and those in amino acids 65 and 106 (Supplementary For tenofovir failure an association was also seen with SNP 1063A in amino acid 91 2 8 5
Identification of novel variants
holding treatment and laboratory monitoring information from the national ART programme in South Africa. The clinical information was entered in anonymised form into a relational 2 8 7 sequence database, the SATuRN REGA database [27] . Further details of the study have been 2 8 8 described previously [28, 29] . The study was approved by the Biomedical Research Ethics Committee of the was obtained from all the study participants and their parent or legal guardian in the case of 2 9 5 paediatric patients (≤16 years). The median duration of ART among patients in this cohort was 42 months (IQR 32-2 9 8 53). The most common first line ART regimens were: tenofovir/stavudine/zidovudine 2 9 9 +Lamivudine +efavirenz/nevirapine. The most common second line ART regimen were:
Lopinavir (+ Ritonavir), Lamivudine, zidovudine/tenofovir. The median duration of 3 0 1 antiretroviral failure was 27 months (IQR 17-40 months). Details on drug exposure data and 3 0 2 DR results have been described previously [28, 29] . Drug exposure was defined by exposure 3 0 3 at any time point prior to sequencing. Table 1 provides a basic description of the 3 0 4 characteristics of the 343 individuals with viral WGS data included in the analysis. (Qiagen). The near complete HIV-1 genome was amplified by a previously described RT- Life Technologies). Pooled amplicons were prepared for sequencing using the Nextera XT samples that included three controls (one negative sample, one inter-run and one intra-run 3 1 7 control). All processes to generate WGS were undertaken locally at the Africa Centre Fastq quality control was performed using FASTQC(0.11.3) and QUASR(3.1) 3 2 2 software applications. Reads of less than 100bp in length and a quality score lower than 30 3 2 3 were excluded. In addition, the reads were trimmed up to 10bp from 5' and 30bp at the 3' to 3 2 4 exclude poor quality sequence at the beginning and end of reads. We noticed that the second 3 2 5 pair read of the Illumina Nextera XT was of lower quality and that excluding the last 30bp 3 2 6 increased quality score to > 33. We imposed these exclusion criteria in order to decrease the 3 2 7 probability of ambiguous read mapping, which occurs when shorter reads of lower accuracy are included in assemblies [30] . Following these quality control steps, we mapped reads 3 2 9
RNA extraction, PCR amplification and whole genome Sequencing
against a subtype C reference sequence (AF411967) with five assembly iterations using
Geneious 8 (http://www.geneious.com) [31] . After assembly, we exported the data as BAM In order to determine if there was clustering of sequences (i.e. sequences that were 3 3 3 very similar with low genetic diversity), we aligned all of the whole genomes with a The processing of WGS data to the performing of GWAS is outlined in Figure 1 was used for a variant to be called. As GWAS software was originally designed for diploid organisms (i.e. those with two 3 4 7 chromosomes and so two copies of any given loci), each sample can be called either as is incorrect in the sense that HIV is haploid, it captures an important reality of viral infection: 3 5 0 genetic differences within the host's viral population. We wanted to retain the feature of 3 5 1 diploidy to account for samples with diversity at a given DR loci. We expected heterozygous either entirely non-existent or fixed. The downside of this approach was that given numerous sequence reads for each loci, some variation is expected due to sequencing errors. To account 3 5 5 for this, we allowed for diploid calling in the following manner. If the reference allele 3 5 6 frequency was present in >85% of reads at a loci, the loci was called as homozygous for the 3 5 7 reference allele. A heterozygous call with one copy of the reference variant and one of the 3 5 8 non-reference variant was made if the reference allele frequency was between 85% and 15% 3 5 9 of reads. Finally, a homozygous non-reference call was made if the reference allele frequency 3 6 0 was found in less than 15% of reads. While these cut-offs are simply defaults of the software, was fixed or mixed for any given loci. First, where multiple alleles occurred at the same loci, the reference variant and the most 3 6 6 common non-reference variant were used to make the loci bi-allelic. Second, a minor allele 3 6 7 frequency of greater than 1% was required for all variants. Lastly, we did not implement a 3 6 8 restriction on missingness of data. In human GWAS, high missingness for a SNP or individual may reflect poor quality genotyping. However, in HIV WGS sequencing quality is 3 7 0 not homogenous across the genome (see Supplementary Figure 2 ). As we had restricted 3 7 1 analysis to calling variants at loci with a depth of 50 or greater, higher missingness was 3 7 2 expected. Missingness for SNPs significantly associated with DR is reported in Table 2 . A logistic regression was performed in PLINK1.09 [35] with drug exposure as the 3 7 5 binary outcome and each SNP as a predictor with an additive effect. All samples exposed to a 3 7 6
given drug were compared to all that were not. To determine genome-wide significance we 3 7 7 performed 10,000,000 permutations within PLINK1.09 both on a single SNP and genome-3 7 8 wide level using the --mperm command. This was performed to account for correlation 3 7 9 between nearby SNPs which would have made Bonferroni correction for the raw number of 3 8 0 statistical tests overly conservative. Given the smaller number of variants compared to a 3 8 1 human GWAS, permutation using 10,000,000 for the empirical p-values was computationally 3 8 2 feasible. As the negative correlations in the prescribing of these drugs existed, associations 3 8 3 with the same SNP were seen in multiple analyses. However it was possible to identify when 3 8 4 exposure was associated with the non-reference sequence (i.e. odds ratio>1) and so, were generated in GCTA [36] . Genome-wide significant SNPs within the Pol region were able to be taken forward 3 8 9
for replication in a publically available independent sample. This was the Stanford University 3 9 0
HIV Drug Resistance Database [19, 20] , where information on amino acid frequencies were 3 9 1 available for sequences exposed to different drugs. This analysis was restricted to the 13,676 3 9 2 subtype C sequences. Additional analyses also made use of a subset of all publically available (http://www.hiv.lanl.gov/). This was done to ensure our variant frequencies were in 3 9 5 agreement with those observed elsewhere. We thank all the patients for their continued support, all Africa Centre staff who contribute to 4 1 2 maintaining ACDIS and the laboratory. The authors have declared that no competing interests exist. : I  D  :  5  2  1  2  2  5  4  3  3  6  7  ;  P  u  b  M  e  d  C  e  n  t  r  a  l  P  M  C  I  D  :  P  M  C  3  3  7  1  8  3  2  .  5  2  2  3  2  .  C  h  e  v  e  n  e  t  F  ,  J  u  n  g  M  ,  P  e  e  t  e  r  s  M  ,  d  e  O  l  i  v  e  i  r  a  T  ,  G  a Figure 1 : Analysis pipeline for HIV whole genome sequence (WGS) genome-wide association study (GWAS) compared to a human study using a SNP chip.
Tables and Figures
Step 1) Diploidy defined for both human and pathogen, to reflect 'real' heterozygosity and heterozygosity from within host viral diversity. 2) While missingness and Hardy-Weinberg Equilibrium are used to assess genotyping quality in human GWAS, in viral GWAS we used depth of sequencing to assess variant calls. As such, higher calling confidence is associated with higher missingness in viral SNPs, while the reverse is true in humans. Low minor allele frequency (MAF) is always used to remove variants that have low power to detect effects and may reflect errors. 3&4) Correction for ancestry and relatedness are key to human GWAS, however due to both more homogenous sampling and difficulty in applying conventional corrections in human data to viral, this was done as a sensitivity test in a smaller sample for top SNPs in HIV GWAS.
Figure 2:
Manhattan plot comparing HIV sequences that were exposed to tenofovir to those that were not. The reference line at p=7E-5 is the line for permutation adjusted genome wide significance. Dashed grey lines on genomic locations refer to borders of genes (black dashed refer to GAG, Pol and ENV). Each marker is a SNP, weighted by it's -log(p-value) to highlight the most significant SNPs. 
